Assiut University Initiates Regulatory Evaluation of Ivermectin Alone or With Microneedling for Cutaneous Warts

By Dr. Hatem Rabeh · Published April 24, 2026 · Updated April 3, 2026

Publication date context: February 19, 2026. A ClinicalTrials.gov entry documents a study on the efficacy of ivermectin alone or with microneedling for cutaneous warts. Sponsored by Assiut University, the trial lists salicylic acid as an additional drug intervention. The study status is not yet recruiting. This article provides a regulatory minded briefing for clinicians, device operators, and regulatory teams who follow drug and device combination trials.

In this article: What changed Who is affected How is the trial designed What are the regulatory considerations How to learn more

What changed

The registry entry for the study shows an evaluation plan that uses ivermectin as a drug and a microneedling procedure as a device based intervention in the context of cutaneous warts. Salicylic acid is listed as a second drug component in the same record. The page does not provide results or endpoint details at this time. The entry identifies the interventions but does not disclose trial design elements such as randomization or sample size.

What is being studied?

The entry lists ivermectin as a drug and microneedling as a device based procedure along with salicylic acid as a drug component. These elements define a combined approach under the trial’s scope. No outcomes are reported on the registry page. The lack of disclosed endpoints means readers should monitor the registry for updates.

Who is affected

The target population is individuals with cutaneous warts. The sponsor named is Assiut University, indicating institutional leadership for the trial. The registry status notes that recruitment has not yet begun as of the current entry. No ethical or safety outcomes are described in the entry.

How is the trial designed

The record lists the interventions but does not disclose specific design details such as endpoints or sample size. The absence of disclosed design elements requires readers to monitor the registry page for updates and to seek official documents for trial specifics. The description aligns to a drug and device based approach, which may implicate multiple regulatory pathways if outcomes are reported.

What are the regulatory considerations

Because the trial involves a drug and a device based procedure the study touches both drug and device regulatory pathways. The sponsor is identified and the interventions are listed but no device level claims or safety data are provided in the entry. Readers should refer to official guidance and the registry for current information and to prepare for subsequent regulatory review if results are reported. The combo nature of the study may require cross disciplinary oversight and careful labeling of any future outcomes as drug counseling and device procedures.

How to learn more

To obtain official information please consult the public registry page for the trial identified by NCT07396714. The entry is accessible via the link below and should be reviewed for updates on status and outcomes.

Conclusion

In summary the registry confirms a regulatory focused evaluation of a drug device combination for wart therapy. The page shows not yet recruiting status and no results. Regulators clinicians and stakeholders should stay informed using the official registry and monitor for updates on outcomes and safety data as they become available.